230 results on '"Kruse, Niels"'
Search Results
2. Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression
3. Neurofilament Light Chain Serum Levels Mirror Age and Disability in Secondary Progressive Multiple Sclerosis: A Cross-Sectional Study.
4. TREM2 expression in the brain and biological fluids in prion diseases
5. Interlaboratory validation of cerebrospinal fluid α-synuclein quantification in the diagnosis of sporadic Creutzfeldt-Jakob disease
6. Evaluation of α-synuclein as a novel cerebrospinal fluid biomarker in different forms of prion diseases
7. Quantification of Alpha-Synuclein in Biological Fluids by Electrochemiluminescence-Based Detection
8. Validation of α-Synuclein as a CSF Biomarker for Sporadic Creutzfeldt-Jakob Disease
9. Molecular Alterations in the Cerebellum of Sporadic Creutzfeldt–Jakob Disease Subtypes with DJ-1 as a Key Regulator of Oxidative Stress
10. Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study
11. Neurofilament light chains in serum as biomarkers of axonal damage in early MS lesions: a histological–serological correlative study
12. TREM2 expression in the brain and biological fluids in prion diseases
13. Cerebrospinal α-synuclein in α-synuclein aggregation disorders: tau/α-synuclein ratio as potential biomarker for dementia with Lewy bodies
14. Quantification of CSF biomarkers using an electrochemiluminescence-based detection system in the differential diagnosis of AD and sCJD
15. Extracellular vesicle sorting of α-Synuclein is regulated by sumoylation
16. Baseline Cerebrospinal Fluid α-Synuclein in Parkinson’s Disease Is Associated with Disease Progression and Cognitive Decline
17. Diagnostic accuracy of cerebrospinal fluid biomarkers in genetic prion diseases
18. Baseline Cerebrospinal Fluid 0̆3b1-Synuclein in Parkinson's Disease Is Associated with Disease Progression and Cognitive Decline
19. Induction of α-synuclein aggregate formation by CSF exosomes from patients with Parkinson’s disease and dementia with Lewy bodies
20. Natalizumab analogon therapy is effective in a B cell-dependent multiple sclerosis model
21. Systematic Assessment of 10 Biomarker Candidates Focusing on α‐Synuclein‐Related Disorders
22. Molecular alterations in the cerebellum of sporadic Creutzfeldt–Jakob disease subtypes with DJ-1 as a key regulator of oxidative stress
23. Identification of distinct pathological signatures induced by patient-derived α-synuclein structures in nonhuman primates
24. Differential expression of BDNF mRNA splice variants in mouse brain and immune cells
25. Anesthesia triggers drug delivery to experimental glioma in mice by hijacking caveolar transport
26. A polymorphism in the human cytotoxic T-lymphocyte antigen 4 (CTLA4) gene (exon 1 +49) alters T-cell activation
27. Recommendations to standardize preanalytical confounding factors in Alzheimerʼs and Parkinsonʼs disease cerebrospinal fluid biomarkers: an update
28. Bidirectional gut-to-brain and brain-to-gut propagation of synucleinopathy in non-human primates
29. Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis
30. HLA-DRB5*0101 and -DRB1*1501 expression in the multiple sclerosis-associated HLA-DR15 haplotype
31. Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis
32. Evaluation of diagnostic relevance of mRNA levels in peripheral blood: predictive value for mortality in hemodialysis patients
33. Effects of Oncostatin M on Human Cerebral Endothelial Cells and Expression in Inflammatory Brain Lesions
34. Genetic polymorphism of the tumor necrosis factor (TNF)-α promoter region in families with localized early-onset periodontitis
35. Autoantibodies to BP180 Associated with Bullous Pemphigoid Release Interleukin-6 and Interleukin-8 from Cultured Human Keratinocytes
36. Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson’s Disease Progression
37. Genomic NGFB variation and multiple sclerosis in a case control study
38. Genetic variation at position –1082 of the interleukin 10 (IL10) promotor and the outcome of multiple sclerosis
39. Antibody‐based methods for the measurement of α‐synuclein concentration in human cerebrospinal fluid – method comparison and round robin study
40. O2‐09‐04: HARMONIZATION OF IMMUNOCHEMICAL METHODS FOR MEASUREMENT OF α‐SYNUCLEIN IN HUMAN CEREBROSPINAL FLUID: A ROUND ROBIN STUDY APPROACH
41. Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: A multi-center, retrospective analysis
42. [P4-151]: ALPHA-SYNUCLEIN BIOMARKER ANALYSIS: ANALYTICAL PERFORMANCE AND INTER-LABORATORY PRECISION USING A NEW COLORIMETRIC ELISA
43. Validation of electrochemiluminescence assays for highly sensitive and reproducible quantification of α-synuclein in cerebrospinal fluid
44. Validation of α-Synuclein as a CSF Biomarker for Sporadic Creutzfeldt-Jakob Disease
45. Molecular Alterations in the Cerebellum of Sporadic Creutzfeldt–Jakob Disease Subtypes with DJ-1 as a Key Regulator of Oxidative Stress
46. Antibody‐based methods for the measurement of α‐synuclein concentration in human cerebrospinal fluid – method comparison and round robin study.
47. Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study
48. Characterizing mild cognitive impairment in incident Parkinson disease:The ICICLE-PD Study
49. Evaluation of α‐synuclein as a novel cerebrospinal fluid biomarker in different forms of prion diseases
50. A First Tetraplex Assay for the Simultaneous Quantification of Total α-Synuclein, Tau, β-Amyloid42 and DJ-1 in Human Cerebrospinal Fluid
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.